… The concept of targeting immune checkpoint receptors for cancer therapy was first pioneered
by James Allison and colleagues in 1996 when CTLA-4 blockade was shown to lead to …

… checkpoint inhibitor therapies. Using a question‐and‐answer format, this review summarizes
the scientific rationale for immune checkpoint inhibitor therapy … checkpoint inhibitor therapy …

… as adjuvant therapy in high-risk resected stage III or IV melanoma. Neoadjuvant checkpoint
inhibition … , which is currently limited to clinical trials, is emerging as a highly effective therapy. …

… Herein we review the clinical development of checkpoint inhibitors and their approval for …
via checkpoint inhibition should allow it to be fully activated to detect and eliminate the cancer. …

BACKGROUND: Immunotherapy, specifically the use of checkpoint inhibitors, offers patients
with cancer an alternative to chemotherapy, targeting different pathways to destroy cancer …

… checkpoint inhibitors have reignited enthusiasm for the development of immunotherapy drugs
for cancer, … high response rates and prolonged overall survival in cancer patients. Immune …

… on the safety of checkpoint inhibition in patients with cancer and preex… therapy, recognizing
the uncertainty surrounding the potential for AEs with respect to the benefits of cancer therapy…

… the rationale for checkpoint inhibitors in lung cancer, recent … In recent years, checkpoint
inhibitors targeting the … of the rationale for checkpoint inhibitors in cancer immunotherapy with a …

… immunotherapies, harnessing the immune system to restore anti-tumor immunity, has
transformed the treatment of certain cancers. The first immune checkpoint inhibitor (ICI), an …

… type non-small cell lung cancer 5 . The recent FDA approval of … checkpoint inhibitors to
target a variety of cancers. Clinical trials that have led to the FDA approval of checkpoint inhibitors …